Secarna Pharmaceuticals publishes new preclinical data in The Journal of Immunology demonstrating potent therapeutic activity of LNAplus™ ASO targeting NLRP3 in highly debilitating autoinflammatory diseases
<ul> <li> Secarnas LNAplus™ ASOs suppress expression of NLRP3, a central component of the inflammasome pathway, which is overactive in many inflammatory diseases </li> <li> Cryopyrin-associated periodic syndrome (CAPS) is a group of rare inherited autoinflammatory diseases driven by overactive NLRP3, resulting in systemic inflammation </li> <li> With NLRP3-specific ASOs, inflammatory downstream effects were interrupted in immune cells a...
Frank Jaschinski Ariel Feldstein Secarna Lnaplus Hal Hoffman Secarna Pharmaceuticals Secarna Pharmaceuticals Gmbh Co
Source: whatech.com